459 results on '"Hideshima, T"'
Search Results
2. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
3. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
4. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
5. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
6. Lenalidomide for the treatment of relapsed and refractory multiple myeloma
7. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
8. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
9. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
10. β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway
11. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
12. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
13. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
14. The use of novel agents in the treatment of relapsed and refractory multiple myeloma
15. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
16. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
17. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
18. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
19. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
20. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
21. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway
22. Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
23. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
24. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
25. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
26. Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma
27. Dendritic cells efficiently internalize and process exogenous peptides despite proteasome inhibition
28. INHIBITION OF THE STK4 KINASE RESTORES THE HIPPO CO-FACTOR YAP1 AND INDUCES DNA-DAMAGE MEDIATED APOPTOSIS IN MULTIPLE MYELOMA CELLS
29. Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma
30. Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
31. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
32. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
33. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
34. The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma
35. The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma
36. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation
37. TARGETING ANGIOGENESIS VIA A C-MYC/HIF-1 alpha-DEPENDENT PATHWAY IN MM
38. Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
39. Targeting PKC: A Novel Role for Beta-catenin in ER Stress and Apoptotic Signaling
40. Upregulation of c-Jun induces cell death via caspase- triggered c-Abl cleavage in human multiple myeloma
41. Targeting PKC informs in MM by enzastaurin (LY317615.HCL)
42. C-jun and C-ABL in human multiple myeloma cell death
43. Targeting proteinkinase C alters ER-stress and b-catenin signaling in multiple myeloma: Therapeutic implications
44. The small-molecule VEGF-receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
45. Occupied and unoccupied electronic structures of an L-cysteine film studied by core-absorption and resonant photoelectron spectroscopies
46. Up-regulation of c-Jun contributes to induction of apoptosis by Adaphostin in human multiple myeloma cells
47. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
48. A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma
49. Fatty acid synthase is a novel therapeutic target in multiple myeloma
50. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.